eMedicine Specialties > Psychiatry > Adult

Phobic Disorders

Author: Adrian Preda, MD, Health Sciences Associate Professor of Psychiatry and Human Behavior, University of California Irvine School of Medicine
Coauthor(s): Ronald C Albucher, MD, Chief Medical Officer, Westside Community Services; Consulting Staff, California Pacific Medical Center
Contributor Information and Disclosures

Updated: Jul 10, 2008

Introduction

Background

A phobia is defined as an irrational fear that produces a conscious avoidance of the feared subject, activity, or situation. The affected person usually recognizes that the reaction is excessive. Phobic disorders can be divided into 3 types: social phobia, specific phobias, and agoraphobia.

The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)1 and its subsequent Text Revision (DSM-IV-TR) defines social phobia as a strong, persisting fear of an interpersonal situation in which embarrassment can occur and specific phobia as a strong, persisting fear of an object or situation. Agoraphobia is defined as the fear of being alone in public places (eg, a supermarket), particularly places from which a rapid exit would be difficult in the course of a panic attack. At least 75% of patients with agoraphobia experience panic disorder as well.

Social phobia, now called social anxiety disorder (SAD), has been described as far back as Hippocrates, when it was called erythrophobia, which is a fear of blushing in front of others. Social anxiety disorder is now considered a disorder distinct from other phobias. In the first 2 versions of the DSM, social phobia was not conceptualized as a stand-alone diagnosis; however, starting with DSM-III-R, the disorder could be diagnosed separately in the presence of multiple social fears and other comorbid conditions.

Specific phobia is more common than social phobia. The following types of specific phobia are described:

  • Animal type (fear of dogs, spiders, snakes, or other animals)
  • Natural environment type (eg, height, water, storm)
  • Blood injection/injury type
  • Situational type (eg, planes, elevators, enclosed spaces)
  • Other

Collectively, these disorders are the most common forms of psychiatric illness, surpassing rates of mood disorders and substance abuse. Anxiety linked to a specific object or situation is the most common subtype. Severity can range from mild and unobtrusive to severe and can result in incapacity to work, travel, or interact with others.

Pathophysiology

Several theories are postulated for the biological etiology of phobic disorders, most focusing on the dysregulation of endogenous biogenic amines. Sympathetic nervous system activation is common in phobic disorders, resulting in elevations in heart rate and blood pressure, as well as symptoms such as tremor, palpitations, sweating, dyspnea, dizziness, and/or paresthesias.2

Psychological theories range from explaining anxiety as a displacement of an intrapsychic conflict (psychodynamic models) to conditioning (learned) paradigms (the cognitive-behavior models). Many of these theories capture portions of the disorder.

A psychoanalyst would likely conceptualize social anxiety as a symptom of a deeper conflict—for instance, low self-esteem or unresolved conflicts with internal objects. The treatment uses exploration with the goal of understanding the underlying conflict. A behaviorist would see phobia as an learned, conditioned response resulting from a past association with a situation with negative emotional valence at the time of association (eg, social situations are avoided because intense anxiety was originally experienced in that setting). Even if no danger is posed in most social encounters, an avoidance response has been linked to these situations. Treatment from this perspective aims to weaken and eventually separate the specific response from the stimulus.

Genetic factors seem to play a role in both social phobia and specific phobia. Based on family and twin studies, the risk for specific phobias and social anxiety appears to be moderately heritable.3,4

Frequency

United States

The National Comorbidity Survey reported the following lifetime (and 30-day) prevalence estimates: 6.7% (and 2.3%) for agoraphobia, 11.3% (and 5.5%) for simple phobia, and 13.3% (and 4.5%) for social phobia.5,6  

Social phobia is the most common anxiety disorder; it has an early age of onset — by age 11 years in about 50% and by age 20 years in about 80% of individuals that have the diagnosis — and it is a risk factor for subsequent depressive illness and substance abuse.7

International

European data generally are similar to those of the United States.

Mortality/Morbidity

Considerable evidence shows that social anxiety results in significant functional impairment and decreased quality of life.8,9 Despite evidence of impairment, only a minority of individuals with simple phobia ever seek professional treatment.

Phobias are highly comorbid. Most comorbid simple and social phobias are temporally primary, while most comorbid agoraphobia is temporally secondary. Comorbid phobias are generally more severe than pure phobias. Social phobia is also frequently comorbid with major depressive disorder and atypical depression, which results in increased disability.9,10

Controversy exists whether anxiety disorders in general and phobias in particular are independently associated with suicidal ideation and suicide attempts (ie, after adjusting for comorbid mental disorders). New evidence suggests that even after adjusting for socio-demographic factors and other mental disorders, baseline presence of any anxiety disorder, including agoraphobia, social phobia, and specific phobias, is significantly associated with suicidal ideation and suicide attempts. Additionally, the presence of any anxiety disorder, phobias included, in combination with a mood disorder appears to increase likelihood of suicide attempts compared with a mood disorder alone.11

Significant morbidity is possible in terms of work and relationships, especially in social phobia and agoraphobia.

Race

The occurrence of phobias appears equally distributed among races.

Sex

  • Specific phobia has a female-to-male ratio of 2:1.
  • Social phobia is more common in women, but more men seek treatment due to career issues.
  • Agoraphobia has a female-to-male ratio of 2-3:1.

Age

Most anxiety disorders appear earlier in life. Animal phobias are most common at the elementary school level. Earlier median ages at illness onset are reported for simple phobia (15 y) and social phobia (16 y) than for agoraphobia (29 y).5

  • Specific phobia: Age of onset depends on the phobia. In general, specific phobia appears earlier than social phobia or agoraphobia. Examples include the following:
    • Animal phobia appears at a mean age of 7 years.
    • Blood phobia appears at a mean age of 9 years.
    • Dental phobia appears at a mean age of 12 years.
    • Claustrophobia appears at a mean age of 20 years.
    • Most simple phobias develop during childhood and eventually disappear. Those that persist into adulthood rarely go away without treatment.
  • Social phobia: Most social phobias begin before age 20 years.
  • Agoraphobia: Agoraphobia usually begins in late adolescence to early adulthood.

Clinical

History

  • Social phobia: Ask the patient about any difficulties in social situations, such as speaking in public, eating in a restaurant, or using public washrooms. Fear of scrutiny by others or of being embarrassed or humiliated is described commonly by people with social phobia.
  • Agoraphobia: Inquire about any intense anxiety reactions that occur when the patient is exposed to specific situations such as heights, animals, small spaces, or storms. Other areas of inquiry should include fear of being trapped without escape (eg, being outside the home and alone; in a crowd of unfamiliar people; on a bridge, in a tunnel, in a moving vehicle).
  • Specific phobias: If specific phobias are suspected, specific questions need to be asked about irrational and out of proportion fear to specific situations (eg, animals, insects, blood, needles, flying, heights).
  • Phobias can be disabling and cause severe emotional distress, leading to other anxiety disorders, depression, suicidal ideation, and substance-related disorders, especially alcohol abuse or dependence. The physician must inquire about these areas as well.

Physical

Anxiety is the most common feature in phobic disorders. Manifestations include the following (which should be asked about and examined):

  • Elevated heart rate
  • Elevated blood pressure
  • Tremor
  • Palpitations
  • Diarrhea
  • Sweating
  • Dyspnea
  • Paresthesias
  • Dizziness
As anxiety manifests with a number of physical symptoms, any patient who presents with a de novo complaint of physical symptoms suggesting an anxiety disorder should have a physical examination and basic laboratory workup to rule out medical conditions that might present with anxiety like symptoms (see Differentials). For a patient who presents for a repeat visit with similar complaints, after medical contributors have been ruled out, a careful Mental Status Examination might be better suited than repeat physical examination and laboratory investigations. While considering anxiety as the primary suspect, the physician should always remember that over time patients with anxiety do develop medical conditions at the same rate as other patients. In other words, a diagnosis of anxiety, while changing the threshold for investigation of physical symptoms, should not deprive the patient of regular follow-up examinations as otherwise indicated.

Mental Status Examination

The physician should assess appearance, behavior, ability to cooperate with the exam, level of activity, speech, mood and affect, thought processes and content, insight, and judgment.

In a situation where the patient is acutely confronted with the object of his or her phobia, the patient's Mental Status Examination is significant for an anxious affect, with a restricted range. Neurovegetative signs (such as tremor or diaphoresis) might be present. The patient also reports feeling anxious (mood) and can clearly identify the reason for his/her anxiety (thought content). The thought content is significant for phobic ideation (unrealistic and out of proportion fears). Insight might be impaired, especially during exposure, but most times the patient has preserved insight and while reporting that they cannot control their feelings, they also acknowledge that the severity of their fears is not justified.

At any other time, a patient with phobic disorder has a mental status within normal limits, with the exception of thought content positive for phobic ideation. Of note, phobic ideas might remain undisclosed unless questions about phobias are specifically asked. Phobias do not present with suicidal or homicidal ideation, but comorbid conditions commonly associated with phobias, including depression and other anxiety disorders, do present with suicidal or homicidal ideation. If comorbid conditions exist, a specific assessment of the suicidal and homicidal risk should also be completed.

Causes

  • Social phobia can be initiated by traumatic social experience (eg, embarrassment) or by social skills deficits that produce recurring negative experiences. A hypersensitivity to rejection, perhaps related to serotonergic or dopaminergic dysfunction, is present. Current thought is that social phobia appears to be an interaction between biological and genetic factors and environmental events.
  • Specific phobia can be acquired by conditioning, modeling, traumatic experience, or even may have a genetic component (eg, blood-injury phobia).
  • Agoraphobia may be the result of repeat, unexpected panic attacks, which, in turn, may be linked to cognitive distortions, conditioned responses, and/or abnormalities in noradrenergic, serotonergic, or gamma-aminobutyric acid (GABA)–related neurotransmission.

More on Phobic Disorders

Overview: Phobic Disorders
Differential Diagnoses & Workup: Phobic Disorders
Treatment & Medication: Phobic Disorders
Follow-up: Phobic Disorders
References

References

  1. American Psychiatric Association. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association Press; 2000.

  2. Mathew SJ, Coplan JD, Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry. 2001;158:1558–1567. [Full Text].

  3. Kendler KS, Karkowski LM, Prescott CA. Fears and phobias: reliability and heritability. Psychol Med. 1999;29:539–553. [Medline].

  4. Liebowitz MR, Klein DF. Fyer AJ, Mannuzza S, Chapman TF, A direct interview family study of social phobia. Arch Gen Psychiatry. 1993;50:286-293. [Full Text].

  5. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey.Arch Gen Psychiatry. Feb 1996;53(2):159-68. [Medline].

  6. Wittchen HU, Fehm L. Epidemiology, patterns of comorbidity, and associated disabilities of social phobia. Psychiatric Clin North Am. 2001;24:617–664. [Medline].

  7. Stein MB, Stein DJ. Social anxiety disorder. Lancet. Mar 2008;371(9618):1115-25. [Medline].

  8. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322–331. [Medline].

  9. Lochner C, Mogotsi M, du Toit PL, Kaminer D, Niehaus DJ, Stein DJ. Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology. 2003;36:255–262. [Medline][Full Text].

  10. Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the national comorbidity survey. Arch Gen Psychiatry. 2003;60:817–826. [Full Text].

  11. Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 62(11);2005 Nov:1249-57. [Medline][Full Text].

  12. de Beurs E, van Balkom AJ, Van Dyck R. Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Acta Psychiatr Scand. Jan 1999;99(1):59-67. [Medline].

  13. Shear MK, Beidel DC. Psychotherapy in the overall management strategy for social anxiety disorder. J Clin Psychiatry. 1998;59 Suppl 17:39-46. [Medline].

  14. Hudson C, Hudson S, MacKenzie J. Protein-source tryptophan as an efficacious treatment for social anxiety disorder: a pilot study. Can J Physiol Pharmacol. Sep 2007;85(9):928-32. [Medline].

  15. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry. May suppl, 1998;155.

  16. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. Sep 1998;155(9):1189-95. [Medline][Full Text].

  17. Michelson D, Lydiard RB, Pollack MH. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. Nov 1998;155(11):1570-7. [Medline][Full Text].

  18. Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety. 1999;9(3):107-16. [Medline].

  19. Lydiard RB. The role of drug therapy in social phobia. J Affect Disord. Sep 1998;50 Suppl 1:S35-9. [Medline].

  20. Van Ameringen M, Allgulander C, Bandelow B. WCA recommendations for the long-term treatment of social phobia. CNS Spectr. Aug 2003;8(8 Suppl 1):40-52. [Medline].

  21. Heimberg RG, Liebowitz MR, Hope DA. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry. Dec 1998;55(12):1133-41. [Medline][Full Text].

  22. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. Sep 1999;100(3):193-8. [Medline].

  23. Stein MB, Fyer AJ, Davidson JR. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. May 1999;156(5):756-60. [Medline].

Further Reading

Keywords

phobic disorders, anxiety disorders, phobias, social phobia, social anxiety disorder, agoraphobia, panic, phobic neurosis, fear, mood disorders

Contributor Information and Disclosures

Author

Adrian Preda, MD, Health Sciences Associate Professor of Psychiatry and Human Behavior, University of California Irvine School of Medicine
Adrian Preda, MD is a member of the following medical societies: International Congress of Schizophrenia Research, Schizophrenia International Research Society, and Society of Biological Psychiatry
Disclosure: Nothing to disclose.

Coauthor(s)

Ronald C Albucher, MD, Chief Medical Officer, Westside Community Services; Consulting Staff, California Pacific Medical Center
Ronald C Albucher, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

Medical Editor

Mohammed A Memon, MD, Medical Director of Geriatric Psychiatry, Department of Psychiatry, Spartanburg Regional Hospital System
Mohammed A Memon, MD is a member of the following medical societies: American Association for Geriatric Psychiatry, American Medical Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Iqbal Ahmed, MBBS, Professor, Department of Psychiatry, John A Burns School of Medicine, University of Hawaii
Iqbal Ahmed, MBBS is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, and American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.